Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06410248 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Triapine in Combination With Temozolomide for the Treatment of Patients With Recurrent Glioblastoma

StatusRecruiting
PhasePhase 1
Started2024-07-23
View on ClinicalTrials.gov ↗
This phase I trial tests the safety, side effects, and best dose of triapine in combination with temozolomide in treating patients with glioblastoma that has come back after a period of improvement (recurrent). Triapine inhibits an enzyme responsible for producing molecules required for the production of deoxyribonucleic acid (DNA), which may inhibit tumor cell growth. Temozolomide is in a class of medications called alkylating agents. It works by damaging the cell's DNA and may kill tumor cells and slow down or stop tumor growth. Giving triapine in combination with temozolomide may be safe, tolerable, and/or effective in treating patients with recurrent glioblastoma.

Amendment history 3 changes detected by DataLookout

2026-09-10
Enrollment reduced: 30 → 22 participants
2026-09-10
Primary completion confirmed: July 2026 (last estimated May 2029)
2026-09-10
Completion pushed: 2030-05-12 → 2030-08-31
Trial Details
NCT Number NCT06410248
Lead Sponsor Northwestern University
Collaborators: National Cancer Institute (NCI), Nanopharmaceutics, BrainUp
Conditions Recurrent Glioblastoma, IDH-Wildtype, Recurrent WHO Grade 2 Glioma, Recurrent WHO Grade 3 Glioma, Recurrent WHO Grade 4 Glioma
Enrollment 22 participants
Start Date 2024-07-23
Primary Completion 2026-07-22 (estimated)
Study Completion 2030-08-31 (estimated)
Updated on ClinicalTrials.gov 2026-09-09